close
Advertisement
Can't connect right now! retry

add The News to homescreen

tap to bring up your browser menu and select 'Add to homescreen' to pin the The News web app

Got it!

add The News to homescreen

tap to bring up your browser menu and select 'Add to homescreen' to pin the The News web app

Got it!
May 23, 2020

Hydroxychloroquine tied to deaths, heart risk in COVID study

Top Story

May 23, 2020

NEW YORK: Antimalaria drugs that US President Donald Trump has touted for treatment of COVID-19 were linked to an increased risk of death and heart ailments in a study, foreign media reported.

Hydroxychloroquine and chloroquine didn’t benefit patients with the coronavirus, either alone or in combination with an antibiotic, according to the study published Friday by The Lancet medical journal.

Researchers are searching through available options to treat the coronavirus, which has killed more than 330,000 people, including drugs like the antimalarials that are also already approved to treat lupus and rheumatoid arthritis. Trump’s endorsement has led many people to take the medications without scientific proof of their benefit.

The study looked at the records of 15,000 people who had been treated with the antimalarials and one of two antibiotics that have sometimes been paired with them. Treatment with any combination of the four drugs was associated with a higher risk of death than seen in 81,000 patients who didn’t receive them. The biggest risk increase was seen in the group treated with hydroxychloroquine and an antibiotic, where 8% of patients who got the combination developed a heart arrhythmia, compared with 0.3% of those in the comparison group. The drugs should only be used for COVID-19 treatment as part of robust studies that will definitively show their impact, the researchers said.

Authors of a separate study that supported the use of antimalaria drugs with antibiotics for COVID-19 requested that their paper be withdrawn, according to the Retraction Watch website. The paper had been posted online May 11 and hadn’t been reviewed or published in a medical journal.

The lead author of the study, Benjamin Davido of the Hopital Raymond Poincare near Paris, declined to comment when reached by telephone. The paper’s text has been replaced with a statement that the authors intend to revise the manuscript because of “controversy about hydroxychloroquine and the retrospective nature of their study.” Only one drug, Gilead Sciences Inc.’s remdesivir, has been shown to benefit coronavirus patients in a clinical trial.